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Summary The expression of the small cell carcinoma (SCLC) antigens cluster-5 (antibody LAM8) and
cluster-5A (antibody SWA20) was examined on a panel of routinely processed biopsy or surgical specimens
of 290 lung tumours by immunoperoxidase staining. Antigen expression was largely restricted to SCLC. Of
over 150 tissue samples evaluated, moderate or strong antigen expression was found in 49% (cluster-5) and
45% (cluster-5A). Concordance in expression of the two antigens was seen in 71% of SCLC samples, with
35% expressing both antigens strongly, 8% moderately and 28% being negative for both antigens. Antigen
expression was independent of the morphological subtype of SCLC. Primary lung tumours of other histology,
including squamous cell carcinoma, large cell carcinoma, adenocarcinoma, mesothelioma or carcinoid had no
significant antigen expression. Of 135 tumours, strong or moderate expression of both antigens was seen only
in two cases. 20%, mostly carcinoids, were weakly positive for cluster 5 and 4% for cluster SA antigen. The
remainder were antigen negative. No significant antigen expression was seen in 25 normal lung tissues. The
membrane antigens of SCLC cluster 5 and 5A are marker for SCLC and their expression in tissues is
tumour-associated.
Small cell lung carcinoma (SCLC) cells express on their
surface membrane a number of structures which have little
or no expression on lung tumour cells of other lineage or on
normal epithelial cells. This was first shown by Baylin by
two-dimensional gel electrophoresis (Baylin et al., 1982) and
later by us and others using monoclonal antibody tech-
niques. Cell surface antigens on SCLC identified by mono-
clonal antibodies can be grouped according to reported
tissue reactivities into epithelial antigens (Stahel et al., 1985),
antigens shared with white blood cells (Bunn et al., 1985;
Cailland et al., 1984), neuroendocrine antigens (De Leij et
al., 1985; Takahashi et al., 1986; Watanabe et al., 1987) and
tumour-associated antigens (Waibel et al., 1987; Waibel et
al., 1988). In the past, it has been very difficult to evaluate
individual antibodies based on the original reports, since
different laboratories varied widely on the material and
methods used for the description of antibody and antigens.
Since the First International Workshop for Small Cell Lung
Cancer Antigens (Souhami et al., 1987), where antibodies
have been analysed comparatively and five clusters of mem-
brane antigens have been identified, the evaluation and
reporting of individual antibodies has been greatly
facilitated.
We have previously reported on the characteristics of two
antibodies, the IgM antibody LAM8 and the IgG2a anti-
body SWA20, which recognise closely related, but not
identical membrane sialoglycoproteins heterogeneously
expressed in SCLC (Stahel et al., 1986; Waibel et al., 1987,
1988). By immunoperoxidase technique both antibodies
stained equally well frozen and formalin fixed tissues of
SCLC, while little or no reactivity was found with non-small
cell carcinomas of lung, extrapulmonary carcinomas, and
normal tissues, including bronchial epithelium and epithe-
lium of the gastrointestinal tract, liver, kidney, pancreas,
lymphoid organs, bone marrow, peripheral nerve and brain.
Because of the virtual absence of expression in normal
tissues, the antigens were called tumour-associated antigens
of SCLC. In the First International Workshop on Small Cell
Lung Cancer Antigens, the antibody LAM8 was designated
to SCLC cluster-5 (CL-5) and the antibody SWA20 to SCLC
cluster-5 associated (CL-5A) (Beverly et al., 1988).
The aim of this study was to determine whether these two
antibodies. could be used in formalin-fixed, paraffin-
embedded biopsy and surgical tissues obtained in a routine
setting, and whether their restrictive reactivity with SCLC
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could be confirmed when larger numbers of tissues of all
types of primary lung tumours were examined.
Materials and methods
Tumour tissues
Tumour tissues were obtained from files of the Institute of
Pathology, Ruhr-University of Bochum, FR Germany. Con-
secutive lung tumour specimens obtained between January
1984 and July 1987 and providing sufficient tumour material
for analysis were included in the study. The specimens
originated from endobronchial biopsies (208 cases), surgical
resections (80 cases) or autopsies (two cases). The histologi-
cal diagnosis was made on the basis of formalin-fixed,
routinely processed paraffin-embedded sections stained with
Haematoxylin and Eosin, van Gieson and PAS stain. One
hundred and fifty-five cases of SCLC, 135 cases of other
primary lung tumours and 25 specimens of normal 'lung
tissues were included in the study.
Antibodies
The mouse monoclonal antibodies used for tissues staining
have been raised against intact SCLC cells of the cell line
SW2. The reactivity of the antibodies with cell lines and a
limited number of tissues and the characterisation of their
antigens as distinct membrane sialoglycoproteins has been
reported (Stahel et al., 1986; Waibel et al., 1987, 1988).
Hybrid culture supernatant was used for this study.
Immunoperoxidase staining
The immunohistochemical staining of tissues with antibodies
LAM8 and SWA20 was performed with the avidin-biotin
method (Vectastain ABC-Kit, Vector Laboratories,
Burlingame, CA, USA). Sections from paraffin-embedded
tissue blocks were cut at 5,um, placed on gelatin covered
glass slides, and incubated at 37°C for 16-18h. The sections
were then deparaffinised in xylene, rehydrated in graded
alcohols and washed in phosphate buffered saline (PBS).
Subsequent incubations were performed at 37°C in a humi-
dity chamber. Endogenous peroxidase activity was quenched
with freshly prepared 1% H202 in methanol for 15 min. The
sections were rinsed twice in PBS before incubation with
normal goat (LAM8) or normal horse serum (SWA20) for
10 min to reduce non-specific background staining. Each
section was exposed to 100pl of antibody (undiluted culture
supernatant) for 2h, thoroughly washed in PBS and then
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incubated with biotinylated goat anti-mouse IgM (LAM8) or
biotinylated horse anti-mouse IgG (SWA20) for Omin. The
samples were again washed in PBS and treated with avidin-
biotin conjugated horseradish peroxidase for 10 min. After
washing in PBS the sections were exposed to freshly
prepared peroxidase substrate (3-amino-9-ethylcarbazole
AEC, H202 in acetate buffer pH 5.2, BioGenex
Laboratories, Dublin, CA, USA) for 15 min, washed in PBS
and counterstained with Mayer's haemalaun. After washing
in PBS and distilled water the sections were mounted in
glycerol gelatin (Serva Feinbiochemica, Heidelberg, FR Ger-
many). Sections of a SCLC incubated with non-immune
mouse serum (BioGenex Laboratories) served as negative
control and sections of a SCLC staining positive with both
antibodies served as positive control. A positive reaction was
indicated by a red cellular deposit evaluated by light micros-
copy. Sections with antibody reactivity were scored accord-
ing to the proportion of tumour cells staining positive using
the following system: + + + + >50% positive cells; + + +
> 10-50% positive cells, + + < 10% positive cells; and + rare
positive cells. In the text + + + + is termed strong positivity,
+ + + moderate positivity and + + and + weak positivity.
Results
The expression of the antigens SCLC CL-5 (LAM8) and CL-
5A (SWA20) was examined in 290 tissue specimens of
primary lung tumours and in 25 normal lung tissues. Rou-
tine formalin-fixed paraffin-embedded tissues were deparaffi-
nised and examined for antigen expression by
immunohistochemical staining. Background staining in
normal tissues surrounding the tumour was absent with
antibody LAM8 and very faint in less than 20% of tissues
with antibody SWA20. The results of immunoperoxidase
staining of primary lung tumours and normal lung tissues
with antibody LAM8 are summarised in Table I. The 155
SCLC tissues examined showed heterogeneous expression
of CL-5 antigen. Strong expression (+ + + + staining) was
present in 26%, moderate expression (+++ + staining) in
23% and weak expression (+ + and + staining) in 20%.
Thirty per cent of tumours were antigen negative. Seventy-
five non-small cell carcinomas were examined. Moderate
antigen expression was only seen in one case termed poorly
differentiated squamous cell carcinoma which on rebiopsy
was classified as SCLC. Weak antigen expression was found
in 10% of large cell carcinomas and 18% of squamous cell
carcinomas. Among the latter this weak positivity was only
seen in moderately well differentiated (3/15) and undifferen-
tiated (4/20) tumours. Mesothelioma did not stain with the
antibody LAM8 and of 50 lung carcinoids only one case was
moderately antigen positive, the remainder were weakly
positive (36%) or negative (62%). The absence of antigen on
normal bronchial epithelial cells and normal lung paren-
chyma with the exception of occasional positivity in sub-
bronchial glands was confirmed on 25 specimens.
The results of tissue staining with antibody SWA20 are
summarised in Table II. Because of insufficient material,
three cases of SCLC were not evaluable. Similar to CL-5
antigen, the CL-5A antigen identified by antibody SWA20
Table I Expression of sialoglycoprotein antigen SCLC CL-5 in primary lung tumours and normal
lung determined by immunoperoxidase staining with antibody LAM8
Intensity of antigen expression
No. cases (%) No. cases
examined ++++ +++ ++ + 0
Small cell carcinoma
Adenocarcinoma
Large cell carcinoma
Squamous cell carcinoma
Mesothelioma
Lung carcinoid
Normal lung bronchus and
parenchyma
155 41
(26)
25 0
(0)
10 0
(0)
40 0
(0)
10 0
(0)
50 0
(0)
25 0
(0)
36
(23)
0
(0)
0
(0)
la
(3)
0
(0)
1
(2)
0
(0)
aBiopsy, on subsequent resection classified as small cell carcinoma.
13
(8)
0
(0)
I
(10)
1
(3)
0
(0)
3
(6)
1
(4)
18
(12)
0
(0)
0
(0)
6
(15)
0
(0)
15
(36)
0
(0)
47
(30)
25
(100)
9
(90)
32
(80)
10
(100)
31
(62)
24
(96)
Table II Expression of sialoglycoprotein antigen SCLC CL-5A in primary lung tumours and
normal lung determined by immunoperoxidase staining with antibody SWA20
Intensity of antigen expression
No. cases (%) No. cases________________________
examined ++++ +++ ++ + 0
Small cell carcinoma 152 32 36 12 9 63
(21) (24) (8) (6) (41)
Adenocarcinoma 25 0 0 0 0 25
(0) (0) (0) (0) (100)
Large cell carcinoma 10 0 0 0 0 10
(0) (0) (0) (0) (100)
Squamous cell carcinoma 40 0 1a 0 1 38
(0) (3) (0) (3) (95)
Mesothelioma 10 0 0 0 0 10
(0) (0) (0) (0) (100)
Lung carcinoid 50 0 1 0 5 44
(0) (2) (0) (10) (88)
Normal lung bronchus and 25 0 0 1 0 24
parenchyma (0) (0) (4) (0) (96)
aBiopsy, on subsequent resection classified as small cell carcinoma.694 A. MAIER et al.
was heterogeneously expressed in SCLC; 21% had strong
expression, 24% moderate expression, 14% weak expression
and 41% were antigen negative. Virtually no reactivity was
seen in other lung primaries. Normal lung bronchial epithe-
lial cells and lung parenchyma were antigen negative, again
with the exception of occasional bronchial glands.
The expression the CL-5 and CL-5A antigens were com-
pared on 152 SCLC tissues. Tissues were grouped by
intensity of staining (negative, weak, or moderate and
strong) and tabulated (Table III). Concordance between
expression of the two antigens was seen in 108 cases (71%).
Fifty-four samples (35%) expressed both antigens strongly or
moderately, 12 (8%) weakly and 42 (28%) expressed neither
antigen. Twelve samples strongly expressed CL-5 antigen,
but were negative for CL-5A, and four samples strongly
expressed CL-5A antigen, but were negative for CL-5.
The question whether antigen expression might be asso-
ciated with a histological subtype of SCLC was investigated.
SCLC were classified morphologically into oat-cell type and
intermediate type according to the WHO classification used
at the time of diagnosis (Anonymous, 1982) and examined
separately for antigen expression. As seen in Table IV, there
was no difference in antigen expression among the morpho-
logical subtypes of SCLC.
Sequential tissue samples with immunohistochemical stain-
ing were obtained from five patients with SCLC (Table V).
The tumours of three patients were positive for both anti-
gens on sequential samples. In two patients in whom a
tumour diagnosis could not be firmly established histo-
logically on the first biopsy, immunohistochemical positivity
also was only seen on the definitive diagnostic specimen.
Discussion
This report on routinely processed lung tissues confirms the
restricted expression of the SCLC antigens CL-5 and CL-5A
in a proportion of SCLC, and the absence of expression
from virtually all lung tumours of other histology. As
observed in our initial studies on a limited number of
specimens (Stahel et al., 1986; Waibel et al., 1988) the
antigen expression in SCLC again was found to be hetero-
geneous. CL-5 and CL-5A antigens were expressed strongly
or moderately in 49 and 45% of SCLC, respectively, 30 and
41% were antigen negative and the remainder had weak
antigen expression. Heterogeneous expression was seen both
in bronchial biopsies as well as in resection specimens. The
reason for the heterogeneity of antigen expression has not
yet been determined. From the findings presented here, it
can be concluded that the antigen expression is not asso-
ciated with a certain histological subtype of SCLC. However,
preliminary evidence from in vitro studies suggests that both
Table III Comparison between expression of SCLC CL-5 and CL-5A antigens in
small cell carcinoma tissues
No. of tissues (%)
SCLC CL-S
0 +/++ +++/++++
0 42 9 12
(27) (6) (8)
SCLC CL-5A +/+ + 0 12 9
(0) (8) (6)
+++/+++ 4 10 54
(3) (7) (35)
Table IV Expression of sialoglycoprotein antigens SCLC CL-5 and CL-5A in small cell carcinoma
according to histological sybtype
Intensity of antigen expression
No. cases (%) No. cases
Histology examined + + + + +++ + + + 0
SCLC CL-5
Oat-cell type 75 18 18 6 7 26
(24) (24) (8) (9) (35)
Intermediate cell type 50 16 11 4 7 12
(32) (22) (8) (14) (24)
Unclassified 30 7 7 3 4 9
(23) (23) (10) (13) (30)
SCLC CL-5A
Oat-cell type 75 12 20 3 8 32
(16) (27) (4) (11) (43)
Intermediate cell type 49 13 9 4 1 22
(27) (18) (8) (2) (45)
Unclassified 28 7 7 5 0 9
(25) (25) (18) (0) (32)
Table V Histological and immunohistochemical findings in patients with small cell carcinomas undergoing repeated biopsies or resections
Ist biopsy 2nd biopsy Tumour resection
Patient Histology CL-S CL-5A Histology CL-S CL-SA Histology CL-S CL-SA
I Squamous cell + + + +++ n.d. n.d. n.d. Small cell + + + + + + +
poorly diff.
2 ? carcinoma + + + +++ Small cell + + + + + n.d. n.d. n.d.
3 Small cell + + + + + Small cell + + + +++ n.d. n.d. n.d.
4 ? small cell - ? small cell Small cell + + + +
5 ? small cell n.d. n.d. n.d. Small cell + + ++ +
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antigens are restricted in their expression to the classic type
of SCLC cell lines (Reeve et al., 1988; Carney & Stahel,
unpublished results).
In addition to SCLC, a large number of other pulmonary
and extrapulmonary tumour cell lines and a limited number
of pulmonary and extrapulmonary tumour tissues have been
previously examined for expression of CL-5 and CL-5A
antigens (Stahel et al., 1986; Waibel et al., 1988). Neither
antigen could be demonstrated on cell lines other than SCLC
by indirect immunofluorescence staining or radioimmuno-
assay and antigen expression was weak or mostly absent in
other pulmonary and extrapulmonary tumour tissues by
immunohistochemical staining. The results presented here
show moderate antigen expression in only two of 135
primary lung tumours other than SCLC. Of these one was
classified as carcinoid, and in the other the diagnosis was
changed from poorly differentiated squamous cell carcinoma
in a biopsy to SCLC in the surgical resected tissue. It thus
follows that the antigens SCLC CL-5 and CL-5A are highly
restricted to SCLC in vitro and in vivo.
The antigens were not expressed in normal bronchial
tissues and lung parenchyma. In the current as in our
previous studies (Stahel et al., 1986; Waibel et al., 1988) only
rare single cells (less than 1%) in some samples of the
bronchial epithelium have been antigen positive. Examin-
ation of primary cultures of bronchial epithelial cells con-
firmed these findings (Bernal et al., 1988). Antigen positivity
could also occasionally be demonstrated in a proportion of
bronchial submucosal glands. In these cases it was difficult
to determine whether the positivity was associated with cells
or mucin. We have previously demonstrated the absence of
the antigens from other normal tissues, including blood cells,
neural and neuroendocrine tissues, liver, kidney and mesen-
chymal tissues (Stahel et al., 1986; Waibel et al., 1988). Thus
a differential expression of both antigens between a propor-
tion of SCLC and normal lung tissues (and other normal
tissues) has now been clearly established.
The antigens identified by antibody LAM8 and SWA20
were found to be co-expressed on SCLC cell lines (Waibel et
al., 1988). The concordance of the intensity of CL-5 and CL-
5A expression on SCLC tissues observed in this study
suggests that a co-expression of the two antigens might also
exist in vivo. Despite being co-expressed on SCLC cell lines,
being sialylated in nature and having similar molecular
weights, CL-5 and CL-5A are not identical antigens. Anti-
bodies LAM8 and SWA20 do not compete for antigen
binding and antibody SWA20 does not react with immuno-
absorbed LAM8 antigen (Waibel et al., 1988). It could be
speculated that SCLC cells expressing the antigens have a
common alteration in the activities of enzymes responsible
for post-translational sialylation of membrane proteins.
Investigation into the biosynthesis of the antigen will help to
answer this question.
The studies presented here suggest that the antibodies
LAM8 and SWA20 might be useful adjuncts in the patholo-
gical diagnosis of SCLC, especially since the antigens they
recognise are resistant to routine formalin-fixation and
paraffin-embedding. However, the fact that only a propor-
tion of small cell tumours strongly express the antigens poses
some limitations. On the other hand, strong tissue staining
appears to be quite specific for SCLC and thus a positive
result would serve as strong support for a lung tumour being
a SCLC. The few sequential biopsies on SCLC in our series
indicate that heterogeneity in staining might not be a major
problem in the diagnostic use of the antibodies.
In addition to diagnostic possibilities, the fact that CL-5
and CL-5A antigens are selectively expressed in a proportion
of SCLC in vivo, but not in normal epithelial cells, white
blood cells or neuroendocrine cells, warrants investigations
into the use of these antigens as targets for radioimaging and
immunotherapy.
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